Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dual targeting, a new strategy for novel PARP inhibitor discovery
Lina Wei, Meizhi Wang, Qiaoyun Wang, et al.
Drug Discoveries & Therapeutics (2021) Vol. 15, Iss. 6, pp. 300-309
Open Access | Times Cited: 10

Showing 10 citing articles:

PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them
Dongha Kim, Hye Jin Nam
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8412-8412
Open Access | Times Cited: 62
Role of PARP-1 structural and functional features in PARP-1 inhibitors development
Alexander Vladimirovich Merkuryev, Egorov Vv
Bioorganic Chemistry (2025) Vol. 156, pp. 108188-108188
Closed Access
Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy
Xiaopeng Peng, Wanyi Pan, Feng Jiang, et al.
Pharmacological Research (2022) Vol. 186, pp. 106529-106529
Closed Access | Times Cited: 21
Recent advances in structural types and medicinal chemistry of PARP-1 inhibitors
Ling Yu, Zhiwei Yan, Youde Wang, et al.
Medicinal Chemistry Research (2022) Vol. 31, Iss. 8, pp. 1265-1276
Closed Access | Times Cited: 12
DNA Methylation Malleability and Dysregulation in Cancer Progression: Understanding the Role of PARP1
Rakesh Srivastava, Niraj Lodhi
Biomolecules (2022) Vol. 12, Iss. 3, pp. 417-417
Open Access | Times Cited: 11
An update on small molecule compounds targeting synthetic lethality for cancer therapy
Jiaxiang Luo, Yang Li, Yiwen Zhang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 278, pp. 116804-116804
Closed Access | Times Cited: 1
Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities
Pingyuan Wang, Wen-Ting Zhu, Yajing Wang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115709-115709
Closed Access | Times Cited: 4
Discovery of novel 2,3,4,5-tetrahydrospiro[benzo[c]azepine-1,1’-cyclohexan]-5-ol derivatives as PARP-1 inhibitors
Ling Yu, Jianhui Li, Jü Zhu, et al.
BMC Chemistry (2023) Vol. 17, Iss. 1
Open Access | Times Cited: 2
Discovery of novel anti-tumor compounds targeting PARP-1 with induction of autophagy through in silico and in vitro screening
Danfeng Shi, Qianqian Pang, Qianyu Qin, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 4
Development of erythrina-based PARP-1/FTase dual-target inhibitors against lung cancer epithelial-mesenchymal transition (EMT) in vivo and in vitro
Ling Yu, Youde Wang, Zhiwei Yan, et al.
Bioorganic Chemistry (2024) Vol. 148, pp. 107480-107480
Closed Access
Page 1

Scroll to top